Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1139 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Durvalumab adjuvant therapy for treating hepatocellular carcinoma at high risk of recurrence after curative treatment	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download
Durvalumab add-on therapy for previously untreated locally advanced cervical cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Cervical cancer	Female Reproductive Cancer	2022	View \| Download
Durvalumab (Imfinzi) monotherapy for advanced or metastatic non-small cell lung cancer (EGFR and ALK wild type) – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Durvalumab (Imfinzi) for locally advanced or metastatic urothelial bladder cancer – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Bladder cancer	Urological Cancer	2017	View \| Download
Dupilumab in addition to controller medications for children aged 6 to 11 years with asthma	controller medications , Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Asthma	Respiratory System	2021	View \| Download
Dupilumab for treating Prurigo Nodularis	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Prurigo nodularis (PN)	Dermatology	2021	View \| Download
Dupilumab for treating eosinophilic oesophagitis in people aged 12 years and older	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Eosinophilic oesophagitis	Gastroenterology , Immunology	2022	View \| Download
Dupilumab for treating Chronic Spontaneous Urticaria in people aged 12 years and older after 1 previous treatment	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Chronic spontaneous urticaria (CSU)	Dermatology	2021	View \| Download
Dupilumab for treating Chronic obstructive pulmonary disease (COPD)	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Chronic obstructive pulmonary disease (COPD)	Respiratory System	2022	View \| Download
Dupilumab for treating bullous pemphigoid	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Bullous pemphigoid	Dermatology	2024	View \| Download